



Recommended Schedule for Administering Doses of PCV13

(Pneumococcal Conjugate Vaccine; Prevnar13™, Wyeth)

Age at this Visit	Vaccination History: Total number of PCV7 and/or PCV13 doses previously received	Recommended PCV13 Dose(s) ¹
2-6 months	0 doses	3 doses, 8 weeks apart; 4 th dose at age 12-15 months
	1 dose	2 doses, 8 weeks apart; 4 th dose at age 12-15 months
	2 doses	1 dose, 8 weeks after the last dose; 4 th dose at age 12-15 months
7-11 months	0 doses	2 doses, 8 weeks apart 3 rd dose at 12-15 months
	1 or 2 doses before age 7 months	1 dose at age 7-11 months; 2 nd dose at age 12-15 months (at least 8 weeks later)
12-23 months	0 doses	2 doses, at least 8 weeks apart
	1 dose before age 12 months	2 doses, at least 8 weeks apart
	1 dose at/after age 12 months	1 dose, at least 8 weeks after the last dose ²
	2 or 3 doses before age 12 months	1 dose, at least 8 weeks after the last dose ²
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 additional dose, at least 8 weeks after the last dose ³
Healthy Children 24-59 months	Any incomplete schedule	1 dose, at least 8 weeks after the last dose ²
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 additional dose, at least 8 weeks after the last dose ³
High Risk Children 24-71 months ⁴	Any incomplete series of 2 <u>or</u> less doses	2 doses, one at least 8 weeks after the last dose and another dose at least 8 weeks later
	Any incomplete series of 3 doses	1 dose, at least 8 weeks after the last dose
	4 doses of PCV7 <u>or</u> Age-appropriate complete PCV7 series	1 additional dose, at least 8 weeks after the last dose ³
High Risk Children 6-18 years ⁵	Whether or not any previous doses of PCV7 or PPSV23 were given	May give one dose, at least 8 weeks after the last PCV7 or PPSV23 dose

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at ages less than 12 months, then the minimum interval is 4 weeks.
- 2) No additional PCV13 doses are indicated for children ages 12 through 23 months who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.
- 3) A single additional dose of PCV13 given at least 8 wks after the last dose of PCV7 is recommended for children ages 14-59 months who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 series (fully vaccinated with PCV7). For children with underlying medical conditions, an additional dose is recommended through age 71 months.
- 4) Children ages 24-71 months with one of the following medical conditions should receive an additional dose of PCV13:
 - Immunocompetent: chronic heart and lung disease, diabetes, cerebrospinal fluid leaks, cochlear implants
 - Immunocompromised: HIV, chronic renal failure or nephrotic syndrome, or diseases associated with immunosuppressive chemotherapy or radiation therapy including neoplasms, leukemia, lymphomas or solid organ transplant.
 - Sickle cell disease and other hemoglobinopathies; congenital or acquired asplenia or splenic dysfunction.
- 5) For children ages 6 through 18 years with functional or anatomic asplenia, including sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant or CSF leak, consider an additional (supplemental) dose of PCV13

References: "Prevention of Pneumococcal Disease in Infants and Children: Use of PCV13 & PPSV23" 12/10/10; "Recommendations of ACIP on Use of MCV4/MenACWY-D for aged 9-23 months at Increased Risk for Meningococcal Disease" 10/14/11 located at www.cdc.gov/vaccines; "Quick Look to Using Prevnar (PCV13)" at <http://www.michigan.gov/immunize> January 11, 2012